Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma

Launched by PRIVO TECHNOLOGIES · May 30, 2023

Keywords

ClinConnect Summary

This clinical trial is studying two new treatments for patients with oral squamous cell carcinoma, a type of cancer that affects the mouth. The trial has two parts: the first part tests a topical treatment called PRV111, which is applied directly to the tumor area to see how well it works and how safe it is. The second part is looking at another treatment, PRV211, which is given directly into the area where the tumor was removed during surgery, focusing mainly on safety.

To participate in the trial, patients must be adults aged 18 or older and have specific types of oral cancer that can be surgically removed. They should be healthy enough for surgery and able to follow the study requirements. Participants can expect to receive either of the two treatments based on their cancer stage, and they will be closely monitored throughout the study. It’s important for potential participants to know that there are certain health conditions and past treatments that could make them ineligible, so discussing their medical history with the research team is essential.

Gender

ALL

Eligibility criteria

• Different diagnosis for ARM 1 \& ARM 2, however the rest of inclusion criteria are the same for both arms:
• In order to be eligible to participate in the study, an individual must meet all of the following criteria:
• • • Diagnosis Arm 1: Pathologically proven and clinically confirmed Tis/CIS of the lip or oral cavity Arm 2: Pathologically proven and clinically confirmed T1-T3, Nx,M0 of the lip or oral cavity
• Criteria for Inclusion for both ARM 1 \& ARM 2:
• • 1. Tumors for which the cytological and architectural changes upon histopathological assessment warrant surgical intervention
• • 2. Adult subjects, men and women, defined by age ≥18 years at the time of screening.
• • 3. Tumor must be accessible, with no evidence of infection or active bleeding.
• • 4. Tumor is amenable to surgical resection within 8 weeks of screening visit (Visit 0).
• • 5. Clinically and/or radiologically measurable tumor.
• • 6. Eastern Collaborative Oncology Group Performance Status of ≤2.
• • 7. Male and female subjects of childbearing potential must agree to use 2 methods of effective contraception from screening and for at least 30 days after the final dose of investigational product. Appropriate birth control is defined as barrier methods with spermicides, oral or parenteral contraceptives and/or intrauterine devices, or naturally or surgically sterile (with documentation in the subject's medical records). Postmenopausal women are defined as presenting at least 12 months' natural spontaneous amenorrhea, or at least 6 weeks following surgical menopause (bilateral oophorectomy). Females of childbearing potential must be non-lactating and have a negative serum hCG within 14 days of treatment initiation.
• • 8. Absence of any serious underlying medical conditions which could impair the ability of the subject to participate in the study.
• • 9. Have a life expectancy of ≥3 months.
• • 10. Willing and able to provide written informed consent.
• • 11. Able to return to study site for treatment and follow-up visits as defined in the Protocol.
• Criteria for Exclusion for both ARM 1 and ARM 2 (unless specified):
• An individual who meets any of the following criteria will be excluded from participation in the study:
• • 1. Subjects that are not eligible for surgery as SOC.
• • 2. Patients with a prior history of invasive squamous cell carcinoma (Arm 1 only)
• • 3. Tumors involving the marginal gingiva (Arm 1 only)
• • 4. Squamous cell carcinoma (SCC) of the oral cavity that received previous radiotherapy.(Arm 1 only)
• • 5. Systemic chemotherapy for the treatment of SCC of the head and neck less than 2 years prior to Screening (Arm 1 only)
• • 6. Concurrent documented malignancy, with the exception of localized SCCs and basal cell carcinoma of the skin Exposure to any investigational agent within 3 months prior to Screening
• • 7. Known allergy or hypersensitivity to platinum-containing agents, or known intolerance to a prior platinum- containing agent, or to any of the excipients, which, in the judgement of the physician will preclude re- exposure to platinum-containing agent
• • 8. Active, uncontrolled infection requiring systemic therapy, such as but not limited to HIV, Syphilis, Hepatitis B, or Hepatitis C
• • 9. Uncontrolled intercurrent illness that would risk subject safety, interfere with the objectives of the Protocol, or limit subject compliance with study requirements, as determined by the Investigator
• • 10. Known or suspected pregnancy, planned pregnancy, or lactation
• • 11. Any medical or psychiatric condition that may compromise the ability to give written informed consent
• • 12. Known diagnosis of oral submucous fibrosis (Arm 1 only)
• • 13. Known diagnosis of trismus (Arm 1 only)